Beneficial effect of the short-chain fatty acid propionate on vascular calcification through intestinal microbiota remodelling

Abstract

Background Vascular calcification is a major cause of the high morbidity and mortality of cardiovascular diseases and is closely associated with the intestinal microbiota. Short-chain fatty acids (SCFAs) are derived from the intestinal microbiota and can also regulate intestinal microbiota homeostasis. However, it remains unclear whether exogenous supplementation with propionate, a SCFA, can ameliorate vascular calcification by regulating the intestinal microbiota. This study was conducted to explore the roles of propionate and the intestinal microbiota in the process of vascular calcification. Methods In total, 92 patients were enrolled consecutively as the observational cohort to analyse the relationship between SCFAs and vascular calcification in both blood and faecal samples. A rat model of vascular calcification was induced by vitamin D3 and nicotine (VDN) to validate the effect of propionate. Differences in the intestinal microbiota were analysed by 16S ribosomal RNA gene sequencing. Faecal microbiota transplantation and Akkermansia muciniphila transplantation experiments were performed to evaluate the functions of the intestinal microbiota. Results The results of the observational cohort study revealed that the levels of SCFAs (particularly propionate) in both blood and faecal samples independently correlated negatively with calcification scores (P < 0.01). To verify the activities of propionate, it was provided to VDN-treated rats, and oral or rectal propionate delivery reshaped the intestinal microbiota, resulted in elevated SCFA production, improved intestinal barrier function and alleviated inflammation, ultimately ameliorating vascular calcification. Furthermore, we demonstrated that transplantation of the propionate-modulated intestinal microbiota induced beneficial outcomes similar to those with oral or rectal propionate administration. Interestingly, linear discriminant analysis (LDA) effect size (LEfSe) revealed that oral or rectal propionate administration and propionate-modulated intestinal microbiota transplantation both enriched primarily Akkermansia. Subsequently, we demonstrated that Akkermansia supplementation could ameliorate VDN-induced vascular calcification in rats. Conclusions Propionate can significantly ameliorate vascular calcification in VDN-treated rats, and this effect is mediated by intestinal microbiota remodelling. The findings in our study indicate that the intestinal tract-vessel axis is a promising target for alleviating vascular calcification.

2′-Fucosyllactose alleviates OVA-induced food allergy in mice by ameliorating intestinal microecology and regulating the imbalance of Th2/Th1 proportion

“…57 Jianlong Yan et al found in their studies that Akkermansia was positively correlated with SCFAs in mice, and then the increasing SCFA may improve the intestinal barrier function and relieve inflammation. 58 Our conclusion was consistent with the above phenomena that after the intervention of 2′-FL, the significant reduction of Firmicutes , Lachnospiraceae , Ruminococcaceae , and Akkermansiaceae caused by FA was effectively relieved. These characteristic strains with variation may be the target of treatment for FA induced by OVA.…”

Revealing the beneficial effects of a dairy infant formula on the gut microbiota of early childhood children with autistic spectrum disorder using static and SHIME® fermentation models

“…41,65 On the other hand, normal contents of propionic acid have recently been linked to improved intestinal barrier function, decreased inflammation, and improved vascular calcification in rats. 66 The increase in propionic acid in our results may have been stimulated by the presence of fermentable sugars (FOS and GOS) present in the MNP.…”

Gut–brain communication mediates the impact of dietary lipids on cognitive capacity

“…In a vitamin D3 and nicotine-induced mouse model, supplementation with propionate of SCFAs lowers the levels of LPSs and protects the barrier to prevent the systemic inflammatory response triggered by intestinal “leakage”. 131 Furthermore, palmitoleic acid (rich in MUFAs) is not equivalent to palmitic acid, and there exists an antagonistic effect between them in terms of inflammation. The anti-inflammatory effects of palmitoleic acid are linked to LPS.…”